GMP – Rociletinib (CO-1686) 1374640-70-6
Rociletinib (CO-1686) is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC). Rociletinib was designed to selectively target both the initial activating EGFR mutations and the dominant acquired T790M resistance mutation, while sparing wild-type, or normal EGFR at anticipated therapeutic doses, with an improved toxicity profile.
| Rociletinib (CO-1686) | |||
| Rociletinib Hydrobromide | N/A | ＞98% | |
| Int 1 | N-[3-[[2-Chloro-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]carbamic acid 1,1-dimethylethyl ester | 1374507-23-9 | ＞98% |
| Int 2 | (3-Aminophenyl)carbamic acid tert-butyl ester | 68621-88-5 | ＞98% |
| Int 3 | 4-(4-Acetyl-1-piperazinyl)-2-(methyloxy)aniline | 1021426-42-5 | ＞98% |
| Int 4 | 1-Acetyl-4-[3-(methyloxy)-4-nitrophenyl]piperazine | 1116229-11-8 | ＞98% |
